58.13 USD
+0.98 (+1.71%)
At close: Feb 6, 2026
58.13 USD
0 (0%)
After Hours: 2/6/2026, 8:20:08 PM
Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 523 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. BMRN is valued quite cheap, while showing a decent growth score. This is a good combination! This makes BMRN very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
- In the past year BMRN was profitable.
- In the past year BMRN had a positive cash flow from operations.
- BMRN had positive earnings in 4 of the past 5 years.
- In the past 5 years BMRN always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 6.83%, BMRN belongs to the best of the industry, outperforming 92.76% of the companies in the same industry.
- With an excellent Return On Equity value of 8.59%, BMRN belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
- BMRN has a better Return On Invested Capital (7.69%) than 94.10% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 18.12%.
- The last Return On Invested Capital (7.69%) for BMRN is above the 3 year average (3.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROIC | 7.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
- BMRN has a better Profit Margin (16.82%) than 92.76% of its industry peers.
- Looking at the Operating Margin, with a value of 20.21%, BMRN belongs to the top of the industry, outperforming 94.67% of the companies in the same industry.
- The Gross Margin of BMRN (81.32%) is better than 85.33% of its industry peers.
- In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
- BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- BMRN has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BMRN has been increased compared to 5 years ago.
- The debt/assets ratio for BMRN has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.50 indicates that BMRN is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.50, BMRN is in the better half of the industry, outperforming 74.29% of the companies in the same industry.
- The Debt to FCF ratio of BMRN is 0.72, which is an excellent value as it means it would take BMRN, only 0.72 years of fcf income to pay off all of its debts.
- BMRN has a better Debt to FCF ratio (0.72) than 94.48% of its industry peers.
- BMRN has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
- BMRN has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: BMRN underperforms 62.29% of its industry peers.
- Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Altman-Z | 5.5 |
ROIC/WACC0.92
WACC8.38%
2.3 Liquidity
- BMRN has a Current Ratio of 4.83. This indicates that BMRN is financially healthy and has no problem in meeting its short term obligations.
- BMRN has a Current ratio (4.83) which is comparable to the rest of the industry.
- A Quick Ratio of 3.10 indicates that BMRN has no problem at all paying its short term obligations.
- BMRN's Quick ratio of 3.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 60.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.00%, which is quite impressive.
- Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 12.39% in the last year.
- Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
3.2 Future
- The Earnings Per Share is expected to grow by 28.19% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 21.85 indicates a rather expensive valuation of BMRN.
- 94.67% of the companies in the same industry are more expensive than BMRN, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (27.93), we can say BMRN is valued slightly cheaper.
- BMRN is valuated correctly with a Price/Forward Earnings ratio of 13.11.
- BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 97.52% of the companies in the same industry.
- BMRN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.85 | ||
| Fwd PE | 13.11 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BMRN is valued cheaply inside the industry as 95.43% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 97.33% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.52 | ||
| EV/EBITDA | 14.21 |
4.3 Compensation for Growth
- BMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- BMRN has a very decent profitability rating, which may justify a higher PE ratio.
- BMRN's earnings are expected to grow with 34.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.99
PEG (5Y)N/A
EPS Next 2Y41.64%
EPS Next 3Y34.83%
5. Dividend
5.1 Amount
- BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
58.13
+0.98 (+1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-27 2025-10-27/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners97.82%
Inst Owner Change-2.63%
Ins Owners0.64%
Ins Owner Change-0.95%
Market Cap11.17B
Revenue(TTM)3.09B
Net Income(TTM)520.42M
Analysts81.88
Price Target94.32 (62.26%)
Short Float %3.88%
Short Ratio2.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-48.87%
Min EPS beat(2)-142.18%
Max EPS beat(2)44.44%
EPS beat(4)3
Avg EPS beat(4)-11.96%
Min EPS beat(4)-142.18%
Max EPS beat(4)44.44%
EPS beat(8)6
Avg EPS beat(8)2.48%
EPS beat(12)9
Avg EPS beat(12)14.79%
EPS beat(16)12
Avg EPS beat(16)-9.32%
Revenue beat(2)1
Avg Revenue beat(2)1.98%
Min Revenue beat(2)-2.53%
Max Revenue beat(2)6.48%
Revenue beat(4)2
Avg Revenue beat(4)1.32%
Min Revenue beat(4)-2.53%
Max Revenue beat(4)6.48%
Revenue beat(8)4
Avg Revenue beat(8)1.53%
Revenue beat(12)5
Avg Revenue beat(12)0.37%
Revenue beat(16)7
Avg Revenue beat(16)0.03%
PT rev (1m)2.44%
PT rev (3m)-1.45%
EPS NQ rev (1m)-32.68%
EPS NQ rev (3m)-35.34%
EPS NY rev (1m)-10.07%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)0.64%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.15%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.85 | ||
| Fwd PE | 13.11 | ||
| P/S | 3.61 | ||
| P/FCF | 13.52 | ||
| P/OCF | 12.22 | ||
| P/B | 1.84 | ||
| P/tB | 1.98 | ||
| EV/EBITDA | 14.21 |
EPS(TTM)2.66
EY4.58%
EPS(NY)4.43
Fwd EY7.63%
FCF(TTM)4.3
FCFY7.39%
OCF(TTM)4.76
OCFY8.18%
SpS16.11
BVpS31.53
TBVpS29.29
PEG (NY)0.99
PEG (5Y)N/A
Graham Number43.44
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| ROCE | 9.17% | ||
| ROIC | 7.69% | ||
| ROICexc | 9.82% | ||
| ROICexgc | 10.68% | ||
| OM | 20.21% | ||
| PM (TTM) | 16.82% | ||
| GM | 81.32% | ||
| FCFM | 26.69% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.72 | ||
| Debt/EBITDA | 0.84 | ||
| Cap/Depr | 106.6% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 85.91 | ||
| Cash Conversion | 129.08% | ||
| Profit Quality | 158.68% | ||
| Current Ratio | 4.83 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 5.5 |
F-Score8
WACC8.38%
ROIC/WACC0.92
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.09%
EPS Next Y22.03%
EPS Next 2Y41.64%
EPS Next 3Y34.83%
EPS Next 5Y28.19%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%4.08%
Revenue Next Year12.66%
Revenue Next 2Y11.16%
Revenue Next 3Y10.76%
Revenue Next 5Y7.22%
EBIT growth 1Y52.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.1%
EBIT Next 3Y41.17%
EBIT Next 5Y23.21%
FCF growth 1Y2529.91%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y559.43%
OCF growth 3Y23.45%
OCF growth 5Y63.99%
BIOMARIN PHARMACEUTICAL INC / BMRN FAQ
Can you provide the ChartMill fundamental rating for BIOMARIN PHARMACEUTICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to BMRN.
What is the valuation status for BMRN stock?
ChartMill assigns a valuation rating of 8 / 10 to BIOMARIN PHARMACEUTICAL INC (BMRN). This can be considered as Undervalued.
Can you provide the profitability details for BIOMARIN PHARMACEUTICAL INC?
BIOMARIN PHARMACEUTICAL INC (BMRN) has a profitability rating of 7 / 10.
What is the financial health of BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The financial health rating of BIOMARIN PHARMACEUTICAL INC (BMRN) is 7 / 10.
What is the expected EPS growth for BIOMARIN PHARMACEUTICAL INC (BMRN) stock?
The Earnings per Share (EPS) of BIOMARIN PHARMACEUTICAL INC (BMRN) is expected to grow by 22.03% in the next year.